{"id":"lansoprazole-domperidone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL480","moleculeType":"Small molecule","molecularWeight":"369.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking H+/K+-ATPase in parietal cells. Domperidone is a peripheral dopamine antagonist that increases gastric contractions and accelerates gastric emptying while reducing nausea and vomiting. Together, they provide dual action for acid-related disorders with improved gastric function.","oneSentence":"Lansoprazole reduces stomach acid by inhibiting the proton pump, while domperidone enhances gastric motility and prevents nausea by blocking dopamine receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:41:05.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD) with associated nausea or dysmotility"},{"name":"Peptic ulcer disease with gastric dysmotility"},{"name":"Functional dyspepsia with acid reflux"}]},"trialDetails":[{"nctId":"NCT03355170","phase":"PHASE4","title":"Cardiac Safety of Lansoprazole and Domperidon Combination","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-01","conditions":"GERD, Cardiac Event, Safety Issues","enrollment":""},{"nctId":"NCT03600974","phase":"","title":"A New System for GERD Diagnosis and Treatment","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2019-02-01","conditions":"GERD","enrollment":200},{"nctId":"NCT02958046","phase":"PHASE4","title":"The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-01","conditions":"Gastroesophageal Reflux Disease","enrollment":12},{"nctId":"NCT02703896","phase":"PHASE4","title":"Prophylaxis for Aspiration of Gastric Contents.","status":"COMPLETED","sponsor":"King Saud University","startDate":"2012-01","conditions":"Pulmonary Aspiration of Gastric Contents","enrollment":1920},{"nctId":"NCT01907633","phase":"","title":"An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-12","conditions":"Death, Sudden, Cardiac","enrollment":15000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duolans"],"phase":"marketed","status":"active","brandName":"Lansoprazole/Domperidone","genericName":"Lansoprazole/Domperidone","companyName":"Neutec Ar-Ge San ve Tic A.Ş","companyId":"neutec-ar-ge-san-ve-tic-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lansoprazole reduces stomach acid by inhibiting the proton pump, while domperidone enhances gastric motility and prevents nausea by blocking dopamine receptors. Used for Gastroesophageal reflux disease (GERD) with associated nausea or dysmotility, Peptic ulcer disease with gastric dysmotility, Functional dyspepsia with acid reflux.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}